01.25.16
Dr. Indranil Nandi has been appointed vice president, R&D at Vertice Pharma. Most recently, Dr. Nandi served as vice president, Generic R&D for Impax Laboratories. Dr. Nandi also held positions of increasing responsibilities at Sandoz, including executive director, Portfolio, Project Management and Scientific Affairs. He also worked in various positions in R&D at Par Pharmaceuticals and Geneva Pharmaceuticals.
"We are delighted to welcome Dr. Nandi to the Vertice Pharma leadership team. Dr. Nandi brings over 15 years of extensive multi-disciplinary expertise in drug development and portfolio management across a broad range of therapeutic areas and dosage forms. Dr. Nandi has a proven track record in drug development and I have every confidence in his ability to lead Vertice's Research & Development efforts. His extensive network and his experience in progressing collaborative projects will be key to building an even more robust product pipeline and driving our growth strategy," said Don DeGolyer, President & Chief Executive Officer of Vertice Pharma.
"We are delighted to welcome Dr. Nandi to the Vertice Pharma leadership team. Dr. Nandi brings over 15 years of extensive multi-disciplinary expertise in drug development and portfolio management across a broad range of therapeutic areas and dosage forms. Dr. Nandi has a proven track record in drug development and I have every confidence in his ability to lead Vertice's Research & Development efforts. His extensive network and his experience in progressing collaborative projects will be key to building an even more robust product pipeline and driving our growth strategy," said Don DeGolyer, President & Chief Executive Officer of Vertice Pharma.
